Goldman initiated coverage on Schrodinger with a new price target
$SDGR
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman initiated coverage of Schrodinger with a rating of Neutral and set a new price target of $19.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/30/2025 | $19.00 | Neutral | Goldman |
| 8/15/2025 | $20.00 | Buy → Neutral | Citigroup |
| 8/14/2025 | $25.00 | Overweight | Barclays |
| 7/3/2025 | $28.00 | Equal-Weight | Morgan Stanley |
| 7/2/2024 | $29.00 | Outperform | Leerink Partners |
| 12/5/2023 | $38.00 | Overweight | KeyBanc Capital Markets |
| 5/5/2023 | $60.00 | Overweight | Piper Sandler |
| 12/19/2022 | $23.00 | Neutral | Goldman |
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Dec. 9, 2025 /PRNewswire/ -- Equity Insider News Commentary – Traditional pharmaceutical strategies are giving ground as breakthrough approvals for gene therapies and mRNA platforms target previously untreatable rare diseases with precision interventions[1]. Healthcare systems integrating AI diagnostic tools now match therapies to individual genetic profiles rather than treating broad populations with reactive symptom management[2]. Five companies positioned at this convergence include Avant Technologies, Inc. (OTCQB:AVAI), Beam Therapeutics Inc. (NASDAQ:BEAM), CRISPR Therapeutics (NASDAQ:CRSP), Rocket Pharmaceuticals, Inc. (NASDAQ:R
Schrödinger, Inc. (NASDAQ:SDGR) today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference. The live presentation will take place on Wednesday, November 19, at 4:00 p.m. GMT (11:00 a.m. ET). The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is lic
Third Quarter Total Revenue of $54.3 Million, Software Revenue of $40.9 Million Updates 2025 Financial Guidance Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended September 30, 2025. "Schrödinger delivered a solid third quarter with software revenue growth of 28%, reflecting the industry's increasing demand for our leading computational platform," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "While we are encouraged by the continued high level of customer engagement as the macroeconomic pressures that have affected the industry stabilize, we have lowered our software revenue growth guidance by two percent to 8% to 13%. This updated
4 - Schrodinger, Inc. (0001490978) (Issuer)
4 - Schrodinger, Inc. (0001490978) (Issuer)
4 - Schrodinger, Inc. (0001490978) (Issuer)
Goldman initiated coverage of Schrodinger with a rating of Neutral and set a new price target of $19.00
Citigroup downgraded Schrodinger from Buy to Neutral and set a new price target of $20.00
Barclays initiated coverage of Schrodinger with a rating of Overweight and set a new price target of $25.00
10-Q - Schrodinger, Inc. (0001490978) (Filer)
8-K - Schrodinger, Inc. (0001490978) (Filer)
SCHEDULE 13G/A - Schrodinger, Inc. (0001490978) (Subject)
Schrödinger, Inc. (NASDAQ:SDGR) today announced the expansion of its leadership team with the appointment of Mannix Aklian as executive vice president, chief commercial officer, global head of software sales and marketing. Mr. Aklian brings more than 25 years of experience in software sales and leadership roles within the biopharmaceutical and technology industries. Mr. Aklian will have global oversight of Schrödinger's account management teams and will be responsible for the continued growth of the company's software business, including the go-to-market strategy for enhancements and new products within Schrödinger's computational platform. "Mannix joins Schrödinger at a pivotal time as w
Schrödinger, Inc. (NASDAQ:SDGR) today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310010062/en/Bridget van Kralingen was appointed to Schrödinger's Board of Directors in March 2025. (Photo: Business Wire) "Bridget has a proven track record of growing global software businesses, and we are pleased to welcome her to our Board," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "Bridget's leadership experience overseeing strategic initiatives at global technology companies, including IBM, will be valuable to Sch
Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory and investment roles within the biopharmaceutical industry. As Schrödinger's CFO, he will lead all aspects of the company's financial operations and investor relations and corporate affairs activities. He will also oversee business development and strategic planning for the company's proprietary pharmaceuticals and biopharmaceutical collaborations. This press release features multim
Third Quarter Total Revenue of $54.3 Million, Software Revenue of $40.9 Million Updates 2025 Financial Guidance Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended September 30, 2025. "Schrödinger delivered a solid third quarter with software revenue growth of 28%, reflecting the industry's increasing demand for our leading computational platform," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "While we are encouraged by the continued high level of customer engagement as the macroeconomic pressures that have affected the industry stabilize, we have lowered our software revenue growth guidance by two percent to 8% to 13%. This updated
Schrödinger (NASDAQ:SDGR) will report its third quarter 2025 financial results on Wednesday, November 5, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharm
Second Quarter Total Revenue of $54.8 Million, Software Revenue of $40.5 Million Maintains Full Year 2025 Revenue Growth Guidance and Lowers Operating Expense Guidance Company to Complete Phase 1 Data Package for SGR-1505 While Exploring Strategic Opportunities for Clinical Development Initial Clinical Data for SGR-3515 and SGR-2921 Expected in Fourth Quarter of 2025 Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended June 30, 2025. "In a highly dynamic macroenvironment, our ability to deliver solid second quarter results and maintain our 2025 revenue growth guidance is a testament to our strong customer relationships and the demand for proven c
SC 13G - Schrodinger, Inc. (0001490978) (Subject)
SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)
SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)